|
1
|
Parazzini F, Vercellini P and Pelucchi C:
Endometriosis: Epidemiology and etiological factorsEndometriosis:
Science and Practice. Wiley-Blackwell; New York, NY: pp. 19–26.
2012, View Article : Google Scholar
|
|
2
|
Tandoi I, Somigliana E, Riparini J,
Ronzoni S, Vigano' P and Candiani M: High rate of endometriosis
recurrence in young women. J Pediatr Adolesc Gynecol. 24:376–379.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vercellini P, Frontino G, Pietropaolo G,
Gattei U, Daguati R and Crosignani PG: Deep endometriosis:
Definition, pathogenesis, and clinical management. J Am Assoc
Gynecol Laparosc. 11:153–161. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vercellini P, Viganò P, Somigliana E and
Fedele L: Endometriosis: Pathogenesis and treatment. Nat Rev
Endocrinol. 10:261–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai EC, Tomancak P, Williams RW and Rubin
GM: Computational identification of Drosophila microRNA genes.
Genome Biol. 4:R422003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim VN: Small RNAs: Classification,
biogenesis, and function. Mol Cells. 19:1–15. 2005.PubMed/NCBI
|
|
7
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012.PubMed/NCBI
|
|
8
|
Rácz Z, Kaucsár T and Hamar P: The huge
world of small RNAs: Regulating networks of microRNAs (review).
Acta Physiol Hung. 98:243–251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schickel R, Boyerinas B, Park SM and Peter
ME: MicroRNAs: Key players in the immune system, differentiation,
tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bueno MJ, de Castro IP and Malumbres M:
Control of cell proliferation pathways by microRNAs. Cell Cycle.
7:3143–3148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chegini N: Uterine microRNA signature and
consequence of their dysregulation in uterine disorders. Anim
Reprod. 7:117–128. 2010.PubMed/NCBI
|
|
12
|
Pan Q and Chegini N: MicroRNA signature
and regulatory functions in the endometrium during normal and
disease states. Semin Reprod Med. 26:479–493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patel N, Tahara S, Malik P and Kalra VK:
Involvement of miR-30c and miR-301a in immediate induction of
plasminogen activator inhibitor-1 by placental growth factor in
human pulmonary endothelial cells. Biochem J. 434:473–482. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Divakaran V and Mann DL: The emerging role
of microRNAs in cardiac remodeling and heart failure. Circ Res.
103:1072–1083. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karbiener M, Neuhold C, Opriessnig P,
Prokesch A, Bogner-Strauss JG and Scheideler M: MicroRNA-30c
promotes human adipocyte differentiation and co-represses PAI-1 and
ALK2. RNA Biol. 8:850–860. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia Y, Chen Q, Zhong Z, Xu C, Wu C, Liu B
and Chen Y: Down-regulation of miR-30c promotes the invasion of
non-small cell lung cancer by targeting MTA1. Cell Physiol Biochem.
32:476–485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gong J, Liu R, Zhuang R, Zhang Y, Fang L,
Xu Z, Jin L, Wang T, Song C, Yang K, et al: miR-30c-1* promotes
natural killer cell cytotoxicity against human hepatoma cells by
targetingthe transcription factor HMBOX1. Cancer Sci. 103:645–652.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F,
Yan Y, Shi J and Hu Y: microRNA-30c negatively regulates
endometrial cancer cells by targeting metastasis-associated gene-1.
Oncol Rep. 27:807–812. 2012.PubMed/NCBI
|
|
19
|
Gils A and Declerck PJ: The structural
basis for the pathophysiological relevance of PAI-I in
cardiovascular diseases and the development of potential PAI-1
inhibitors. Thromb Haemost. 91:425–437. 2004.PubMed/NCBI
|
|
20
|
Yildiz Yasar S, Kuru P, Oner Toksoy E and
Agirbasli M: Functional stability of plasminogen activator
inhibitor-1. ScientificWorldJournal. 2014:8582932014.PubMed/NCBI
|
|
21
|
Zhou A, Huntington JA, Pannu NS, Carrell
RW and Read RJ: How vitronectin binds PAI-1 to modulate
fibrinolysis and cell migration. Nat Struct Biol. 10:541–544. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wind T, Hansen M, Jensen JK and Andreasen
PA: The molecular basis for anti-proteolytic and non-proteolytic
functions of plasminogen activator inhibitor type-1: Roles of the
reactive centre loop, the shutter region, the flexible joint region
and the small serpin fragment. Biol Chem. 383:21–36. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cesari M, Pahor M and Incalzi RA:
Plasminogen activator inhibitor-1 (PAI-1): A key factor linking
fibrinolysis and age-related subclinical and clinical conditions.
Cardiovasc Ther. 28:e72–e91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fay WP, Eitzman DT, Shapiro AD, Madison EL
and Ginsburg D: Platelets inhibit fibrinolysis in vitro by both
plasminogen activator inhibitor-1-dependent and-independent
mechanisms. Blood. 83:351–356. 1994.PubMed/NCBI
|
|
25
|
Kozlova N, Jensen JK, Chi TF, Samoylenko A
and Kietzmann T: PAI-1 modulates cell migration in a LRP1-dependent
manner via β-catenin and ERK1/2. Thromb Haemost. 113:988–998. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Czekay RP, Wilkins-Port CE, Higgins SP,
Freytag J, Overstreet JM, Klein RM, Higgins CE, Samarakoon R and
Higgins PJ: PAI-1: An integrator of cell signaling and migration.
Int J Cell Biol. 2011:5624812011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Placencio VR, Miyata T and DeClerck YA:
Pharmacologic inhibition of PAI-1 increases apoptosis and inhibits
macrophage migration in cancer. Cancer Research. 73:Abstract 1548.
2013. View Article : Google Scholar
|
|
28
|
Loskutoff DJ, Curriden SA, Hu G and Deng
G: Regulation of cell adhesion by PAI-1. Apmis. 107:54–61. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee CC and Huang TS: Plasminogen activator
inhibitor-1: The expression, biological functions, and effects on
tumorigenesis and tumor cell adhesion and migration. J Cancer Mole.
1:25–36. 2005.
|
|
30
|
Erem C, Ersoz HO, Karti SS, Ukinç K,
Hacihasanoglu A, Değer O and Telatar M: Blood coagulation and
fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest.
25:345–350. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Binder BR, Christ G, Gruber F, Grubic N,
Hufnagl P, Krebs M, Mihaly J and Prager GW: Plasminogen activator
inhibitor 1: Physiological and pathophysiological roles. News
Physiol Sci. 17:56–61. 2002.PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Somigliana E, Vigano' P, Parazzini F,
Stoppelli S, Giambattista E and Vercellini P: Association between
endometriosis and cancer: A comprehensive review and a critical
analysis of clinical and epidemiological evidence. Gynecol Oncol.
101:331–341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Witz CA: Current concepts in the
pathogenesis of endometriosis. Clin Obstet Gynecol. 42:566–585.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Laschke MW and Menger MD: In vitro and in
vivo approaches to study angiogenesis in the pathophysiology and
therapy of endometriosis. Hum Reprod Update. 13:331–342. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Casslen B, Urano S and Ny T: Progesterone
regulation of plasminogen activator inhibitor 1 (PAI-1) antigen and
mRNA levels in human endometrial stromal cells. Thromb Res.
66:75–87. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bruse C, Radu D and Bergqvist A: In situ
localization of mRNA for the fibrinolytic factors uPA, PAI-1 and
uPAR in endometriotic and endometrial tissue. Mol Hum Reprod.
10:159–166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lagos-Quintana M, Rauhut R, Yalcin A,
Meyer J, Lendeckel W and Tuschl T: Identification of
tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bruchova H, Merkerova M and Prchal JT:
Aberrant expression of microRNA in polycythemia vera.
Haematologica. 93:1009–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tanic M, Yanowsky K, Rodriguez-Antona C,
Andrés R, Márquez-Rodas I, Osorio A, Benitez J and Martinez-Delgado
B: Deregulated miRNAs in hereditary breast cancer revealed a role
for miR-30c in regulating KRAS oncogene. PloS One. 7:e388472012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bandrés E, Cubedo E, Agirre X, Malumbres
R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and
García-Foncillas J: Identification by real-time PCR of 13 mature
microRNAs differentially expressed in colorectal cancer and
non-tumoral tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang G, Zhang H, He H, Tong W, Wang B,
Liao G, Chen Z and Du C: Up-regulation of microRNA in bladder tumor
tissue is not common. Int Urol Nephrol. 42:95–102. 2010. View Article : Google Scholar : PubMed/NCBI
|
